In the preceding three months, 16 analysts have released ratings for Globus Medical GMED, presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 6 | 2 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 3 | 2 | 0 | 0 | 0 |
| 2M Ago | 3 | 3 | 1 | 1 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $91.31, a high estimate of $115.00, and a low estimate of $78.00. Surpassing the previous average price target of $81.81, the current average has increased by 11.61%.
Investigating Analyst Ratings: An Elaborate Study
The analysis of recent analyst actions sheds light on the perception of Globus Medical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Richard Newitter | Truist Securities | Raises | Hold | $90.00 | $85.00 |
| Jason Wittes | Roth MKM | Raises | Buy | $115.00 | $100.00 |
| Ryan Zimmerman | BTIG | Raises | Buy | $91.00 | $87.00 |
| Vik Chopra | Wells Fargo | Raises | Overweight | $95.00 | $88.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $92.00 | $85.00 |
| Drew Ranieri | Morgan Stanley | Raises | Overweight | $100.00 | $83.00 |
| Drew Ranieri | Morgan Stanley | Raises | Equal-Weight | $83.00 | $74.00 |
| Mathew Blackman | Stifel | Raises | Buy | $92.00 | $80.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $85.00 | $79.00 |
| Jason Wittes | Roth MKM | Maintains | Buy | $100.00 | $100.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $92.00 | $80.00 |
| Vik Chopra | Wells Fargo | Raises | Overweight | $88.00 | $78.00 |
| Matt O'Brien | Piper Sandler | Raises | Overweight | $100.00 | $80.00 |
| Craig Bijou | B of A Securities | Raises | Underperform | $80.00 | $55.00 |
| Ryan Zimmerman | BTIG | Raises | Buy | $78.00 | $77.00 |
| Shagun Singh | RBC Capital | Raises | Outperform | $80.00 | $78.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Globus Medical. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Globus Medical compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Globus Medical's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into Globus Medical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Globus Medical analyst ratings.
Discovering Globus Medical: A Closer Look
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.
Globus Medical's Economic Impact: An Analysis
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Globus Medical's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 63.1%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Globus Medical's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 8.28%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Globus Medical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.29%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Globus Medical's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.03%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.13, Globus Medical adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Significance of Analyst Ratings Explained
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
